Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Atkinson, V. G. Hauschild, A. Long, G. V. Mandala, M. Kicinski, M. Govaerts, A. S. Klauck, I. Ouali, M. Lorigan, Paul C Eggermont, A. M. M.
Atkinson, V. G.
Hauschild, A.
Long, G. V.
Mandala, M.
Kicinski, M.
Govaerts, A. S.
Klauck, I.
Ouali, M.
Lorigan, Paul C
Eggermont, A. M. M.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Atkinson VG, Hauschild A, Long GV, Mandala M, Kicinski M, Govaerts AS, et al. Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Asia-Pacific Journal of Clinical Oncology. 2022 Nov;18:115-. PubMed PMID: WOS:000871956500012.